This PDF is the current document as it appeared on Public Inspection on 12/19/2013 at 08:45 am.
Department of the Army, DoD.
Announcement is made of the availability for licensing of the invention set forth in U.S. Provisional Patent Application Serial No. 61/762,543, entitled “Antibody-Dependent Cellular Cytoxicity (ADCC)-Mediating Antibodies,” filed on February 8, 2013. The United States Government, as represented by the Secretary of the Army, has rights to this invention.
Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 21702-5012.Start Further Info
FOR FURTHER INFORMATION CONTACT:
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research and Technology Applications (ORTA), (301) 619-6664, both at telefax (301) 619-5034.End Further Info End Preamble Start Supplemental Information
The invention relates to Antibody-Dependent cellular cytoxicity (ADCC)-mediating antibodies, and, in particular, to ADCC-mediating antibodies (and fragments thereof) suitable for use, for example, in reducing the risk of HIV-1 infection in a subject. The invention further relates to compositions comprising such antibodies or antibody fragments.Start Signature
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2013-30367 Filed 12-19-13; 8:45 am]
BILLING CODE 3710-08-P